479 related articles for article (PubMed ID: 26943983)
21. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Marrs JC; Saseen JJ
Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
[TBL] [Abstract][Full Text] [Related]
22. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
[TBL] [Abstract][Full Text] [Related]
23. Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients.
Kaysen GA
Blood Purif; 2017; 43(1-3):196-199. PubMed ID: 28114129
[TBL] [Abstract][Full Text] [Related]
24. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
[TBL] [Abstract][Full Text] [Related]
25. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients.
Shoji T
Clin Exp Nephrol; 2014 Apr; 18(2):257-60. PubMed ID: 24072417
[TBL] [Abstract][Full Text] [Related]
26. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.
Tonelli M; Wanner C;
Ann Intern Med; 2014 Feb; 160(3):182. PubMed ID: 24323134
[TBL] [Abstract][Full Text] [Related]
27. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.
Hou W; Lv J; Perkovic V; Yang L; Zhao N; Jardine MJ; Cass A; Zhang H; Wang H
Eur Heart J; 2013 Jun; 34(24):1807-17. PubMed ID: 23470492
[TBL] [Abstract][Full Text] [Related]
28. Chronic kidney disease and statin eligibility.
Vega GL; Wang J; Grundy SM
J Clin Lipidol; 2021; 15(1):173-180. PubMed ID: 33191195
[TBL] [Abstract][Full Text] [Related]
29. Dyslipidemia: management using optimal lipid-lowering therapy.
Ito MK
Ann Pharmacother; 2012 Oct; 46(10):1368-81. PubMed ID: 23032652
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
31. Dyslipidaemia in patients with chronic kidney disease - a neglected cardiovascular risk factor.
Essop MR; Seedat F; Raal FJ
S Afr Med J; 2023 Nov; 113(11):35-40. PubMed ID: 38525632
[TBL] [Abstract][Full Text] [Related]
32. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease.
Marrs JC
Am J Manag Care; 2011 Dec; 17 Suppl 15():S403-11. PubMed ID: 22214475
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
34. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014.
Mefford MT; Rosenson RS; Deng L; Tanner RM; Bittner V; Safford MM; Coll B; Mues KE; Monda KL; Muntner P
J Am Heart Assoc; 2019 Jan; 8(2):e010640. PubMed ID: 30651020
[TBL] [Abstract][Full Text] [Related]
35. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
[TBL] [Abstract][Full Text] [Related]
36. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
[TBL] [Abstract][Full Text] [Related]
37. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
38. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
39. Lipid lowering for secondary prevention of cardiovascular disease in older adults.
Thomas JE; Tershakovec AM; Jones-Burton C; Sayeed RA; Foody JM
Drugs Aging; 2010 Dec; 27(12):959-72. PubMed ID: 21087066
[TBL] [Abstract][Full Text] [Related]
40. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.
Anderson TJ; Grégoire J; Pearson GJ; Barry AR; Couture P; Dawes M; Francis GA; Genest J; Grover S; Gupta M; Hegele RA; Lau DC; Leiter LA; Lonn E; Mancini GB; McPherson R; Ngui D; Poirier P; Sievenpiper JL; Stone JA; Thanassoulis G; Ward R
Can J Cardiol; 2016 Nov; 32(11):1263-1282. PubMed ID: 27712954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
